The Cytokine Network in Psoriasis

Archives of Dermatology

Volumn 127, Issue 6, 1991, Pages 871-884

  Nickoloff, Brian J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

EDITORIAL; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS;

CYTOKINES; EPIDERMIS; HUMAN; KERATINOCYTES; MODELS, GENETIC; MUTATION; PSORIASIS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025831330     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1991.01680050115015     Document Type: Article

References (166)

1. Farber EM, Nall ML, Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol. 1974; 109: 207-211.
2. Krueger GG, Bergstresser PR, Lowe NJ, Voorhees JJ, Weinstein GD. Psoriasis. J Am Acad Dermatol. 1984; 11: 937-947.
3. Balkwill FR, Burke F. The cytokine network. Immunol Today. 1999; 10: 299-304.
4. Nickoloff BJ. Cytokine networks in skin diseases. In: Remick D, Kunkel S, eds. Cytokines in Health and Disease. New York, NY: Marcel-Decker. In press.
5. Fry L. Psoriasis. Br J Dermatol. 1988; 119: 445-461.
6. Farber EM, Roth RJ, Ascheim E, Eddy DD, Epinette WW. Role of trauma in isomorphic response in psoriasis. Arch Dermatol. 1965; 91: 246-251.
7. Nickoloff BJ, Karabin GD, Barker JNWN, et al. Cellular localization of interleukin-8 and its inducer tumor necrosis factoralpha in psoriasis. Am J Pathol. 1991; 138: 129-140.
8. Cohn Z. The activation of mononuclear phagocyte: fact, fancy, and future. J Immunol. 1978; 121: 813-816.
9. Lewis T. The Blood-Vessels of the Human Skin and Their Responses. London, England: Shaw & Sons; 1927.
10. Cox AJ. Mast cells in psoriasis. In: Farber EM, Cox AJ, eds. Psoriasis. New York, NY: Yorke Medical Books; 1977: 36-43.
11. Klein LM, Lavker RM, Matis WL, Murphy GF. Degranulation of human mast cells induces an endothelial antigen central to leukocyte adhesion. Proc Natl Acad Sci U S A. 1989; 86: 8972-8976.
12. Nathan CF. Secretory products of macrophages. J Clin Invest. 1987; 79: 319-326.
13. Nickoloff BJ, Griffiths C. Lymphocyte trafficking in psoriasis. J Invest Dermatol. 1990; 95(suppl): 35s-37s.
14. Poulter LW, Campbell DA, Munro C, Janossy G. Discrimination of human macrophages and dendritic cells by means of monoclonal antibodies. Scand J Immunol. 1986; 24: 351-357.
15. Fivenson DP, Nickoloff BJ, Krull EA. Thy-1+ dermal dendrocytes in mycosis fungoides. Clin Res. 1990; 38: 421. Abstract.
16. Nickoloff BJ. The human progenitor cell antigen (CD34) is localized on endothelial cells, dermal dendritic cells, and perifollicular cells in formalin-fixed normal skin, and on proliferating endothelial cells and stromal spindle-shaped cells in Kaposi's sarcoma. Arch Dermatol. 1991; 127: 523-529.
17. Epstein WL. Ultrastructural heterogeneity of epithelioid cells in cutaneous organized granulomas of diverse etiology. Arch Dermatol. 1991; 127: 821-826.
18. Ramirez-Bosca A, Martinez-Ojeda L, Valcuende-Cavero F, Castells-Rodellas A. A study of local immunity in psoriasis. Br J Dermatol. 1988; 119: 587-595.
19. Kupper TS. Immune and inflammatory processes in cutaneous tissues. J Clin Invest. 1990; 86: 1783-1789.
20. Krueger GG, Jederberg WW, Oyden BE, Reese DL. Inflammatory and immune cell function in psoriasis, II: monocyte function, lymphokine production. J Invest Dermatol. 1978; 71: 195-201.
21. Springer TA, Dustin ML, Kishimoto TK, Marlin SD. The lymphocyte function associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Ann Rev Immunol. 1987; 5: 223-252.
22. Dale HH, Camb ND. Some chemical factors in the control of the circulation. Lancet. 1929; 1: 1285-1290.
23. Fitch F, Lancki D, Hauran W. Koch's postulates and the molecular biology of T-cell function. Immunol Today. 1988; 9: 41-43.
24. Goldyne ME. Leukotrienes: clinical significance. J Am Acad Dermatol. 1984; 10: 659-668.
25. Wong E, Camp RD, Greaves MW. The responses of normal and psoriatic skin to single and multiple topical application of leukotriene B4. J Invest Dermatol. 1985; 84: 421-423.
26. Barker JNWN, Karabin GD, Stoof TJ, Sarma VJ, Dixit VM, Nickoloff BJ. Detection of interferon-gamma mRNA in psoriatic epidermis by polymerase chain reaction. J Dermatol Sci. 1991; 2: 106-111.
27. Gomi T, Shiohara T, Munakata T, Imanish K, Nagashima M. Interleukin-1α, tumor necrosis factor-α, and interferon-γ in psoriasis. Arch Dermatol. 1991; 127: 827-830.
28. Bjerke JR, Livden JK, Degre M, Matre R. Interferon in suction blister fluid from psoriatic lesions. Br J Dermatol. 1983; 108: 295-299.
29. Murloch M, Navaseria H, Balkwill F, Trousdale J, Leigh I. Tumor necrosis factor and psoriasis. Br J Dermatol. 1989; 119(suppl 33): 46. Abstract.
30. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A. 1986; 83: 1670-1674.
31. Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP. Detection of transforming growth factor alpha in normal, malignant and hyperproliferative human keratinocytes. J Exp Med. 1988; 167: 670-674.
32. Turbitt ML, Akhurst RJ, White SI, MacKie RM. Localization of elevated transforming growth factor-alpha in psoriatic epidermis. J Invest Dermatol. 1990; 95: 229-232.
33. Grossman M, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A. 1989; 86: 6367-6371.
34. Oxholm A, Oxholm P, Stabeg B, Bendtzen K. Interleukin-6 in the epidermis of patients with psoriasis before and during PUVA treatment. Acta Derm Venereol (Stockh). 1989; 69: 195-198.
35. Oxholm A, Oxholm P, Staberg B, Bendtzen K. Expression of interleukin-6 like molecules and tumor necrosis factor after topical treatment of psoriasis with a new vitamin D analogue (MC903). Acta Derm Venereol (Stockh). 1989; 69: 385-390.
36. Prens EP, Benne K, van Damme J, et al. Interleukin-1 and interleukin-6 in psoriasis. J Invest Dermatol. 1990; 95: 121s-124s.
37. Gearing AJH, Fincham NJ, Bird CR, et al. Cytokines in skin lesions of psoriasis. Cytokine. 1990; 2: 68-75.
38. Christophers E, Schroder JM, Mrowietz U. Identification of two endogenous neutrophil-activating peptides in psoriatic skin and inflammatory cells: C5a and NAP-1. Dermatologica. 1989; 179(suppl): 9-15.
39. Barker JNWN, Sarma V, Mitra RS, Dixit VM, Nickoloff BJ. Marked synergism between tumor necrosis factor-a and interferon-γ in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. J Clin Invest. 1990; 85: 605-608.
40. Griffiths CEM, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol. 1989; 20: 617-629.
41. Singer K, Tuck DT, Sampson HA, Hall RP. Epidermal keratinocytes express the adhesion molecule intercellular adhesion molecule-1 in inflammatory dermatoses. J Invest Dermatol. 1989; 92: 746-750.
42. Vejlsgaard GL, Ralfkiaer E, Aunstorp C, et al. Kinetics and characterization of intercellular adhesion molecule-1 (ICAM-1) expression on keratinocytes in various inflammatory skin lesions and malignant cutaneous lymphomas. J Am Acad Dermatol. 1989; 20: 782-790.
43. Nickoloff BJ, Fivenson DP, Griffiths C, Modlin R. Preferential but not unique cutaneous endothelial cell expression of ELAM1. Clin Res. 1991; 39: 153. Abstract.
44. Picker LJ, Kishimoto TK, Smith CW, Warnock RA, Butcher EC. ELAM-1 is an adhesion molecule for skin-homing T cells. Nature. 1991; 349: 796-799.
45. Chin YH, Falanga V, Streilein JW, Sackstein R. Lymphocyte recognition of psoriatic endothelium: evidence for a tissue-specific receptor/ligand interaction. J Invest Dermatol. 1989; 93(suppl): 82S-87S.
46. Fierlbeck G, Rasner G, Muler G. Psoriasis induced at injection site by recombinant gamma interferon. Arch Dermatol. 1990; 126: 315-355.
47. Nathan CF, Kaplan G, Lewis WR, et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med. 1986; 315: 6-15.
48. Granstein RD, Rook A, Flotte TJ, et al. A controlled trial of intralesional recombinant interferon-γ in the treatment of keloidal scarring. Arch Dermatol. 1990; 126: 1295-1302.
49. Piquet PF, Gran GE, Vassalli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol. 1990; 136: 103-110.
50. Dowd PM, Camp RDR, Greaves MW. Human rIL1α is proinflammatory in normal human skin. Skin Pharmacol. 1988; 1: 30-37.
51. Rampart M, Van Damme J, Zonnekeyn L, Herman AG. Granulocyte chemotactic protein/interleukin-8 induces plasma leakage and neutrophil accumulation in rabbit skin. Am J Pathol. 1989; 135: 21-25.
52. Van Osselaer N, Van Damme J, Rampart M, Herman AG. Increased microvascular permeability in vivo response to intradermal injection of neutrophil-activating protein (NAP-2) in rabbit skin. Am J Pathol. 1991; 138: 23-27.
53. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and interferon-γ induce distinct patterns of endothelial activation and associated leukocyte accumulation. Am J Pathol. 1989; 135: 121-133.
54. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet. 1986; 1: 1466-1468.
55. Shiohara T, Kobayashi M, Abe K, Nagashima M. Psoriasis occurring predominantly on warts: possible involvement of interferon-alpha. Arch Dermatol. 1988; 124: 1816-1821.
56. Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg SA. Interleukin-2 and psoriasis. Arch Dermatol. 1988; 124: 1811-1815.
57. Larrick JW. Native interleukin-1 inhibitors. Immunol Today. 1989; 10: 61-66.
58. Nickoloff BJ, Basham TY, Torseth J, Merigan TC, Morhenn VB. Human keratinocyte-lymphocyte reactions in-vitro. J Invest Dermatol. 1986; 87: 11-18.
59. Nickoloff BJ. Keratinocytes produce a lymphocyte inhibitory factor which is partially reversible by an antibody to transforming growth factor-beta. Ann N Y Acad Sci. 1989; 548: 312-320.
60. Nicholas JF, Karserlian D, Dardennem, Faure M, Thivolet J. Epidermal cell derived lymphocyte differentiating factor (ELDIF) inhibits in-vitro lymphoproliferative responses and interleukin-2 production. J Invest Dermatol. 1987; 88: 161-166.
61. Schwarz T, Urbanska A, Gschnait F, Luger TA. UV-irradiated epidermal cells produce a specific inhibitor of interleukin-1 activity. J Immunol. 1987; 138: 1457-1462.
62. Eisenberg SP, Evans RJ, Arend WP, et al. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 1990; 343: 341-346.
63. Bigler CF, Weston WL, Norris DA, Arend WP. Interleukin-1 receptor antagonist production by human keratinocytes. Clin Res. 1991; 39: 19A. Abstract.
64. Takematsu H, Suzuki R, Tagami H, Kumagai K. Interleukin-1-like activity in horny layer extracts: decreased activity in scale extracts of psoriasis and sterile pustular dermatoses. Dermatologica. 1986; 172: 236-240.
65. Ullrich SE, McIntyre BW, Rivas JM. Suppression of the immune response to alloantigen by factors released from ultravioletirradiated keratinocytes. J Immunol. 1990; 145: 489-498.
66. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J. 1991; 5: 171-177.
67. Daynes RA, Araneo BA, Dowell TA, et al. Regulation of murine lymphocyte production in vivo, III: the lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med. 1990; 171: 979-996.
68. Wierenga E, Swock M, Groot C, et al. Evidence for compartmentalization of functional subsets of CD4 + T lymphocytes in an atopic patient. J Immunol. 1990; 144: 4651-4656.
69. Boguniewicz M, Jaffe HS, Izu A, et al. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med. 1990; 88: 365-370.
70. Morhenn VB, Pregerson-Rodan K, Mullen RH. Use of recombinant interferon gamma administered intramuscularly for the treatment of psoriasis. Arch Dermatol. 1987; 123: 1633-1637.
71. Issekutz TB, Stoltz JM, van der Meide P. The recruitment of lymphocytes into the skin by T cell lymphokines: the role of γ-interferon. Clin Exp Immunol. 1988; 73: 70-75.
72. Barker JNWN, Allen MH, MacDonald DM. The effect of invivo gamma interferon on the distribution of LFA-1 and ICAM-1 in normal human skin. J Invest Dermatol. 1989; 93: 439-442.
73. Morhenn VB. Keratinocyte proliferation in wound healing and skin diseases. Immunol Today. 1988; 9: 104-107.
74. Nickoloff BJ, Varani J, Mitra RS. Modulation of keratinocyte biology by gamma interferon: relevance to cutaneous wound healing: In: Clinical and Experimental Approaches to Dermal and Epidermal Repair: Normal and Chronic Wounds. New York, NY: Wiley-Liss Inc; 1991: 141-154.
75. Nickoloff BJ. Interferon and cutaneous metabolism. In: Goldsmith LA, ed. Biochemistry and Physiology of the Skin. New York, NY: Oxford University Press. In press.
76. Liu YM, Janeway CA. Interferon 7 plays a critical role in induced cell death of effect of T cell: a possible third mechanism of self-tolerance. J Exp Med. 1990; 172: 1735-1739.
77. Gaspari A, Jenkins M, Katz SI. Class II MHC-bearing keratinocytes induce antigen-specific unresponsiveness in hapten specific TH1 class. J Immunol. 1988; 141: 2216-2220.
78. Skoglund C, Scheyuius A, Holmahl R, van der Meide PH. Enhancement of DTH reaction and inhibition of the expression of class II transplantation antigens by in vivo treatment with antibodies against gamma interferon. Clin Exp Immunol. 1988; 71: 428-432.
79. Mansbridge JN, Knapp AM. Changes in keratinocyte maturation during wound healing. J Invest Dermatol. 1987; 89: 253-263.
80. Morhenn VB, Abel E, Mahrle G. Expression of HLA-DR antigen in skin from patients with psoriasis. J Invest Dermatol. 1982; 78: 165-168.
81. Nickoloff BJ, Basham TY, Merigan TC, Morhenn VB. Keratinocyte class II histocompatibility antigen expression. Br J Dermatol. 1985; 112: 373-374.
82. Baker BS, Swain AF, Valdimarsson H, Fry L. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol. 1984; 110: 555-557.
83. Aubock J, Romani N, Grubauer G, Fritsch P. HLA-DR expression on keratinocytes is a common feature of diseased skin. Br J Dermatol. 1986; 114: 465-471.
84. Barker JNWN, Ophir J, MacDonald DM. Keratinocyte HLA-DR expression: the relationship to dermal lymphocyte infiltration. Clin Exp Dermatol. 1987; 12: 397-402.
85. Gottlieb AB, Fu DM, Carter DM, Fotino M. Marked increase in the frequency of psoriatic arthritis in psoriatic patients with HLA-DR+ keratinocytes. Arthritis Rheum. 1987; 30: 901-907.
86. Terui T, Aiba S, Kato T, Tanaka T, Tagami H. HLA-DR antigen expression on keratinocytes in highly inflamed parts of psoriatic lesions. Br J Dermatol. 1987; 116: 87-93.
87. Tuder RM, Young R, Karasek M, Bensch K. Adult cutaneous hemangiomas are composed of nonreplicating endothelial cells. J Invest Dermatol. 1987; 89: 594-597.
88. Nanney LB, Stoscheck CM, Magid M, King LE. Altered (125I) epidermal growth factor binding and receptor distribution in psoriasis. J Invest Dermatol. 1986; 86: 260-265.
89. Weinstein GD, Frost P. Abnormal cell proliferation in psoriasis. J Invest Dermatol. 1968; 50: 254-259.
90. Elder JT, Klein SB, Tavakkol A, et al. Growth factor and proto-oncogene expression in psoriasis. J Invest Dermatol. 1990; 95(suppl): 75-95.
91. Shuster S. Research into psoriasis—the last decade. BMJ. 1971; 3: 236-239.
92. Braun-Falco O, Christophers E. Structural aspects of initial psoriatic lesions. Arch Dermatol Res. 1974; 251: 95-110.
93. Bergstresser PR, Gilliam JN. The immunology of psoriasis. Pharmacol Ther. 1981; 14: 345-354.
94. Cormane RH. Immunopathology of psoriasis. Arch Dermatol Res. 1981; 270: 201-215.
95. Morhenn VB, Orenberg EK, Kaplan J, Pfendt E, Terrell C, Engleman EG. Inhibition of a Langerhans cell-mediated immune response by treatment modalities useful in psoriasis. J Invest Dermatol. 1983; 81: 23-27.
96. Valdimarsson H, Baker BS, Jonsdittir I, Fry L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today. 1986; 7: 256-259.
97. Gottlieb AB. Immunologic mechanisms in psoriasis. J Am Acad Dermatol. 1988; 18: 1376-1380.
98. Baadsgaard O, Fisher G, Voorhees JJ, Cooper KD. The role of the immune system in the pathogenesis of psoriasis. J Invest Dermatol. 1990; 95(suppl): 32s-34s.
99. Griffiths CEM, Barker JNWN, Kunkel S, Nickoloff BJ. Modulation of leukocyte adhesion molecules, a T cell chemotaxin and a regulatory cytokine in allergic contact dermatitis (rhus dermatitis). Br J Dermatol. 1991; 124: 519-526.
100. Barker JNWN, Mitra RS, Griffiths CEM, Dixit VM, Nickoloff BJ. Keratinocytes as initiators of inflammation. Lancet. 1991; 337: 211-214.
101. Vogel J, Hinrichs SM, Reynolds RK, Luciw PA, Jay G. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature. 1988; 335: 606-611.
102. Duvic M, Johnson T, Rapini RP, Freese T, Rios A. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol. 1987; 123: 1622-1632.
103. Leonard JM, Abramcank JW, Pezen DS, et al. Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science. 1988; 242: 1665-1670.
104. Mahoney SE, Duvic M, Nickoloff BJ, et al. HIV transcripts identified in HIV-related psoriasis and Kaposi's sarcoma lesions. J Clin Invest. In press.
105. Sundberg JP, Beamer WG, Schultz LD, Dunstan RW. Inherited mouse mutations as models of human adnexal, cornification, and papulosquamous dermatoses. J Invest Dermatol. 1990; 965(suppl): 625-635.
106. Heng MCY, Moy RL, Lieberman J. α1-Antitrypsin deficiency in severe psoriasis. Br J Dermatol. 1985; 112: 129-133.
107. Brion DE, Raynaud F, Plet A, Laurent P, Leduc B, Anderson W. Deficiency of cyclic AMP-dependent protein kinases in human psoriasis. Proc Natl Acad Sci U S A. 1986; 83: 5272-5276.
108. Groudine M, Weintraub H. Propagation of globin DNAase I-hypersensitive sites in absence of factors required for induction: a possible mechanism for determination. Cell. 1982; 30: 131-139.
109. Payne CMER. Psoriatic science. BMJ. 1987; 295: 1158-1159.
110. Virchow R. Cellular Pathology. London, England: John Churchill; 1860: 33.
111. Shelley WB, Juhlin L. Langerhans cells form a reticuloendothelial trap for external contact antigens. Nature. 1976; 261: 46-47.
112. Liu SC, Parsons CS. Serial cultivation of epidermal keratinocytes from psoriatic plaques. J Invest Dermatol. 1983; 81: 554-551.
113. Baker BS, Powles AV, Valdimarsson H, Fry L. An altered response by psoriatic keratinocytes to gamma interferon. Scand J Immunol. 1988; 28: 735-740.
114. Nickoloff BJ, Mitra RS, Elder JT, Fisher GJ, Voorhees JJ. Decreased growth inhibition by recombinant gamma interferon is associated with increased transforming growth factor-α production in keratinocytes cultured from psoriatic lesions. Br J Dermatol. 1989; 121: 161-174.
115. Hell E. A stimulant to DNA synthesis in guinea-pig ear epidermis. Br J Dermatol. 1970; 83: 632-636.
116. Kohase M, May LT, Tamm I, Vilcek J, Sehgal PB. A cytokine network in human diploid fibroblasts: interaction of β-interferon, tumor necrosis factor, platelet-derived growth factor, and interleukin-1. Mol Cell Biol. 1987; 7: 273-280.
117. Langer JA, Pestka S. Interferon receptors. Immunol Today. 1988; 9: 393-400.
118. Wuepper KD, Coulter SN, Haberman A. Psoriasis vulgaris: a genetic approach. J Invest Dermatol. 1990; 95: 2s-4s.
119. Mitra RS, Nickoloff BJ. Epidermal growth factor (EGF) decreases gamma interferon (IFN-γ)receptors and induction of intercellular adhesion molecule-1 (ICAM-1) on keratinocytes (abstract) J Invest Dermatol. 1991; 96: 544.
120. Nickoloff BJ, Mitra RS. Inhibition of 125I-epidermal growth factor binding to cultured keratinocytes by antiproliferative molecules gamma interferon, cyclosporin A, and transforming growth factor-beta. J Invest Dermatol. 1989; 93: 799-803.
121. Polverini PJ, Solt DB. Effect of in-vivo carcinogens exposure on colony formation and growth of hamster buccal pouch keratinocytes in culture. Lab Invest. 1986; 54: 432-441.
122. Moroco JR, Solt DB, Polverini PJ. Sequential loss of suppressor genes for three specific functions during in-vivo carcinogenesis. Lab Invest. 1990; 63: 298-306.
123. Weinberg RA. A short guide to oncogenes and tumor-suppressor genes. J NIH Res. 1991; 3: 45-58.
124. Hochglaube J, Karasek M. Chromosome studies of normal and psoriatic skin fibroblasts. Arch Dermatol. 1965; 92: 195-199.
125. Nielsen J, Zachariae H. Chromosome aberration in severe psoriasis. Acta Dermatovenereol (Stockh). 1973; 53: 192-194.
126. Petersen GB, Christiansen JV, Voetmann E, Therkelsen AJ. Chromosome aberrations in infected and uninfected skin of patients with psoriasis. Acta Derm Venereol (Stockh). 1974; 54: 147-151.
127. Omar A, Wiesmann UN, Krebs A. Polyploidization and hemiploidization induced by PUVA in vivo. Dermatologica. 1979; 159: 195-209.
128. Kane CJM, Knapp AM, Mansbridge JN, Hanawalt PC. Transforming growth factor β1 localization in normal and psoriatic epidermal keratinocytes in situ. J Cell Physiol. 1990; 144: 144-150.
129. Pietenpol JA, Stein RW, Moran E, et al. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes in abrogated by viral transforming proteins with pRB binding domains. Cell. 1990; 61: 777-785.
130. Stanbridge EJ. Identifying tumor suppressor genes in human colorectal cancer. Science. 1990; 247: 12-13.
131. Folkman J. Angiogenesis in psoriasis: therapeutic implications. J Invest Dermatol. 1972; 59: 40-48.
132. Malhotra R, Stenn KS, Fernandez LA, Braverman IM. Angiogenic properties of normal and psoriatic skin associated with epidermis, not dermis. Lab Invest. 1989; 61: 162-165.
133. Wolf JE. Angiogenesis in normal and psoriatic skin. Lab Invest. 1989; 61: 139-142.
134. Kumar S, West DC. Psoriasis, angiogenesis and hyaluronic acid. Lab Invest. 1990; 62: 664-665.
135. Parent D, Bernard BA, Desbas C, Heenen M, Darmon MY. Spreading of psoriatic plaques: alteration of epidermal differentiation precedes capillary leakiness and anomalies in vascular morphology. J Invest Dermatol. 1990; 95: 333-340.
136. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990; 248: 76-79.
137. Studzinski GP, Moore DC, Carter DL. Suppressor genes: restraint of growth of tumor progression. Lab Invest. 1990; 63: 279-282.
138. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppression-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A. 1990; 87: 6624-6628.
139. Nickoloff BJ, Riser BL, Mitra RS, Dixit VM, Varani J. Inhibitory effect of gamma interferon on cultured human keratinocyte thrombospondin production, distribution, and biologic activities. J Invest Dermatol. 1988; 91: 213-218.
140. Leibovich ST, Polverini PJ, Sheperd HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-α. Nature. 1987; 329: 630-632.
141. Cormane RH, Hamerlinck F, Siddiqui AH. Immunologic implication of PUVA therapy in psoriasis vulgaris. Arch Dermatol Res. 1979; 265: 245-267.
142. Fry L. Immunointervention in skin disorders. J Autoimmun. 1988; 1: 593-601.
143. Nickoloff BJ, Fisher GJ, Mitra RS, Voorhees JJ. Additive and synergistic antiproliferative effects of cyclosporin A and gamma interferon on cultured human keratinocytes. Am J Pathol. 1988; 131: 12-18.
144. Urabe MD, Kanitakis J, Viac J, Thivolet J. Cyclosporin A inhibits directly in-vivo keratinocyte proliferation of human skin. J Invest Dermatol. 1989; 92: 755-757.
145. Petzelbauer P, Stingl G, Wolff K, Volc-Platzer B. Cyclosporin A suppresses ICAM-I expression by papillary endothelium in healing psoriatic plaques. J Invest Dermatol. 1991; 96: 362-369.
146. Nickoloff BJ. Role of interferon-γ in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch Dermatol. 1988; 124: 1835-1843.
147. Niederweiser D, Aubock J, Troppmair I, et al. IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in-vitro alloimmune responses. J Immunol. 1988; 140: 2556-2564.
148. Simon JC, Cruz PD, Bergstresser PR, Davis LS, Tigelaar RE. Phorbol myristate acetate-activated keratinocytes stimulate proliferation of resting peripheral blood mononuclear lymphocytes via a MHC-independent, but protein kinase C and intercellular adhesion molecule-1 dependent mechanism. J Immunol. 1991; 146: 476-484.
149. Schopf RE, Hoffman A, Jung M, et al. Stimulation of T cells by autologous mononuclear leukocytes and epidermal cells in psoriasis. Arch Dermatol Res. 1986; 279: 89-94.
150. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990; 248: 705-711.
151. Cunningham AL, Noble JR. Role of keratinocytes in human recurrent herpetic lesions: ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in-vitro. J Clin Invest. 1989; 83: 490-496.
152. Baardsgaard O, Gupta AK, Taylor S, et al. Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells. J Invest Dermatol. 1989; 92: 190-195.
153. Heng MCY, Kloss SG. Cell interactions in psoriasis. Arch Dermatol. 1985; 121: 881-887.
154. White SH, Newcomer VD, Mickey RM, Terasaki PI. Disturbance of HLA-A antigen frequency in psoriasis. N Engl J Med. 1972; 287: 470-473.
155. Fleischauer K, Kernan NA, O'Reilly RJ, Dupont B, Yang SY. Bone marrow allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med. 1990; 323: 1818-1822.
156. Baadsgaard O, Tong P, Elder JT, et al. UM4D4+ (CD w 60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions. J Invest Dermatol. 1990; 95: 275-282.
157. Stoof TJ, Mitra RS, Sarma VJ, Dixit VM, Nickoloff BJ. Binding by T lymphocytes triggers keratinocyte activation. Br J Dermatol. Abstract. In press.
158. van Els CAC, Bueger MM, Kempenaar J, Ponec M, Coulmy E. Susceptibility to human male keratinocytes to MHC-restricted H-Y-specific lysis. J Exp Med. 1989; 170: 1469-1474.
159. Nikaein A, Phillips C, Gilbert SC, et al. Characterization of skin-infiltrating lymphocytes in patients with psoriasis. J Invest Dermatol. 1991; 96: 3-9.
160. Polla BS. A role for heat shock proteins in inflammation? Immunol Today 1988; 9: 134-137.
161. Asarnow DM, Goodman T, LeFrancois L, Allison JP. Distinct antigen receptor of two classes of murine epithelium-associated T cells. Nature. 1989; 341: 60-62.
162. Shiohara T, Moriya N, Gotoh C, et al. Loss of epidermal integrity by T cell-mediated attack induces long-term resistance to subsequent attack. J Exp Med. 1990; 171: 1027-1041.
163. Takashima A, Morita A. Genomic phenotypic, and functional analysis of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment. J Invest Dermatol. 1991; 96: 376-382.
164. Eedy DJ, Burrows D, Bridges JM, Jones FGC. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ. 1990; 300: 908-909.
165. Gardembas-Pain M, Ifrah N, Foussand C, et al. Psoriasis after allogenic bone marrow transplantation. Arch Dermatol. 1990; 126: 1523.
166. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin G. Cell. 1990; 61: 1315-1327.